An Uncharacteristic Presentation of Evans Syndrome Following Treatment With Dupilumab

• Published in: Curēus (Palo Alto, CA) CA), 2021-07, Vol.13 (7)
• Main Authors: Rutherford, Megan, Tran, Minh, Salazar, Leonardo, Iqbal, Fatima, Mazharuddin, Anam, Camarena, Julieanna
• Format: Article
• Language: English
• Subjects: Hematology; Internal Medicine; Ophthalmology
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.16658

Evans syndrome is a rare autoimmune disorder where patients develop autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and less commonly immune neutropenia. Patients typically present with fatigue, pallor, jaundice, petechiae, or epistaxis. A 27-year-old man with a history of atopic dermatitis for which he recently began treatment with dupilumab presented to the emergency department with a headache and blurry vision. Multiple Roth spots were seen on fundoscopic examination. Laboratory studies were consistent with warm AIHA, confirmed by a positive direct antiglobulin test (DAT), and severe thrombocytopenia. He was diagnosed with Evans syndrome. He was treated with corticosteroids, rituximab, and intravenous immunoglobulin (IVIG). His recovery was prolonged with the slow improvement of anemia and thrombocytopenia. This is an atypical presentation of Evans syndrome with isolated symptoms of new-onset blurry vision and headache along with the finding of Roth spots. Another interesting feature in the case is the recent use of dupilumab. Dupilumab is a monoclonal antibody that inhibits the T-helper cells type 2 (Th2) signaling pathway by blocking interleukin (IL)-4 and IL-13 binding. This alteration in the immune response could have a role in the development of Evans syndrome.